Welcome to our dedicated page for Biostem Tech SEC filings (Ticker: BSEM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Biostem Tech's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Biostem Tech's regulatory disclosures and financial reporting.
BioStem Technologies, Inc. files a Form 10 to register its Common Stock and describe its business, assets and regulatory position. The company reports the January 21, 2026 acquisition of certain surgical and wound-care assets from BioTissue, including the Neox® and Clarix® trademarks, patents and a commercial organization; a Supply Agreement with BioTissue for up to three years of outsourced manufacture; and a conditional transfer of commercial rights to the Catalyze 510(k)-cleared product following BioTissue’s June 2026 510(k) clearance, with a targeted incorporation and potential launch in the fourth quarter of 2026. The filing describes BioStem’s perinatal tissue allograft platforms (BioRetain®, CryoTek®, SteriTek®), enrollment counts for randomized DFU and VLU trials completed or closed in 2025–2026, reimbursement and reimbursement-risk dynamics under Medicare (HCPCS/Q-code, LCDs), reliance history on a single distributor (Venture Medical provided ~99% of revenue in 2024–2025; ~13% of revenue in Q1 2026), and extensive patent, trademark and license tables.